Phytopharm (PYM) ニュース

Buy more shares now to bring your overall share price down. Great buying opportunity at these decade lows. Don’t look a gift horse in the mouth. Be thankful, not critical…..lol

Of course, im being very sarcastic. Mark Smith and his dream team have failed the investors who have support

Thanks. I may have stretched by pigeonholing the GSK deal as immunology, but it does bring the potential for GSK to expand into KIT immunology, as you noted.

SNL has nothing on the Hub.

Best entertainment forum on the web.

TPP

Those meds do wonders.

Like I said last week - this small BS run is over. There was no reason for it to begin with.

This will be back to .001 - .002 in no time.

GVSI is a regulatory disaster and a scam.

WE READY ?...7 mil.buy at .0003 just hit..need more chunky buys.

That Fontalk website looks very impressive!

The day by day of non news will be a slow drop in CLNV price.
The CLNV price drop will speed up as the end of the month gets closer
CLNV will be hitting .015 range next.

If we start February and there is NO NEWS then CLNV should expect
CLNV price back to LOW teen

nice news

$ILLR: AI-Driven Innovation
With cutting-edge AI integrations, Triller is providing creators unparalleled tools to amplify their reach and engagement. Invest in technology. Invest in Triller. #AIFuture #ILLR

Sold NVDA 10 Puts, would have liked to sell 15, but I do not like the trend for the short term.

$ILLR: AI-Driven Innovation
With cutting-edge AI integrations, Triller is providing creators unparalleled tools to amplify their reach and engagement. Invest in technology. Invest in Triller. #AIFuture #ILLR

$ILLR: Monetization at Its Core
Our focus on enhancing monetization tools gives creators a platform to turn their passion into profit. Triller is the backbone of creator success. #InvestSmart #ILLR

$ILLR: Monetization at Its Core
Our focus on enhancing monetization tools gives creators a platform to turn their passion into profit. Triller is the backbone of creator success. #InvestSmart #ILLR

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)

Updates 2025 expected revenue range to $1.5 to 2.5 billion

Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for addit

UMAV $$$ SO CRAZY UNDERVALUED HERE.....SHOULD BE HEADING TO MULTI-DOLLARS....WAIT TILL TRUMP GETS IN THE MARKETS WILL GO CRAZY, TO THE MOON..

Great post! There are some good stocks you've mentioned and some worth looking further into.
FWIW, I've probably never listed every stock I own. Many that you list I've either owned in the past or still do. I am quite diverse. Of the ones you listed, I currently own (and in the same industry)

is there someone home here?

33m ask at 5

Kiwi, I own eypt. Phase 2 trial ends this month. Should be positive. The phase 3 that ocular is running should also be positive. Based on the phase 1 results. Considering a trade.
Sleven,

Yes indeed and with a revenue of $4 billion in the near future (within 1 to 2 years) an MC of almost $100 billion.
And in anticipation of this turnover an MC of $35 billion after approval is not so crazy.
Not bad either, right?
Just keep shorting, then at least you know what to

Knowing this is a low floater ... estimated 50-70 million max. ... someone is collecting.


1 Jan 2025
0.00975
0.00375
62.50%
0.0081
0.00975
0.0041
654,861

1 Jan 2024
0.006
0.00245
69.01%

LFAP SEC registration revoked:

https://www.sec.gov/files/litigation/opinions/2025/34-102149.pdf

Someone sold to me .0004 more...goodness volume